NHS Spending Spree: Will Increased Medicine Budgets Drive Pharma Innovation?

The NHS, a cornerstone of British society, is facing a complex challenge: how to balance rising healthcare demands with finite resources. In 2023-24, the NHS in England spent a staggering £19.9 billion on medicines, medical devices, and related supplies. This accounts for nearly 12% of the Department of Health and Social Care’s day-to-day spending. As the population ages and the prevalence of chronic diseases increases, the pressure on the NHS medicines budget is only set to intensify, with projections estimating a 3% annual rise, reaching £232 billion by 2028-29. This begs the question: will this increased spending truly fuel pharmaceutical innovation, or will it simply perpetuate a cycle of escalating costs?

The Voluntary Scheme: A Double-Edged Sword?

To manage the rising costs, the NHS has a long-standing agreement with the pharmaceutical industry known as the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). Under this deal, branded drug manufacturers must pay back a percentage of their revenue, currently around 23%, if sales exceed pre-agreed caps. In 2025, the VPAG is expected to return £3.5 billion to the NHS, with £2.8 billion going directly to NHS England.

While these rebates help sustain access to expensive but necessary treatments, the pharmaceutical industry argues that these caps reduce their profits and discourage R&D investment. Some warn they may reduce UK-based research or clinical trials if conditions don’t improve. The Association of the British Pharmaceutical Industry (ABPI) has been vocal about the need for a more competitive environment that rewards pharmaceutical innovation fairly.

Innovation or Just Inflation?

A critical question is whether the increased spending translates into genuine innovation or merely reflects price inflation. A 2024 Lancet study estimated that new drugs delivered 3.8 million quality-adjusted life years (QALYs) to NHS patients, but at a cost of £75 billion over the last decade. The study concluded that the cumulative population-health impact of drugs recommended by NICE was negative, with a net loss of approximately 1.3 million QALYs. This raises concerns about whether the NHS is getting the best value for its money and whether alternative spending on mental health, social care, or public health might offer more “bang for the buck.”

UK’s R&D Landscape: Strengths and Weaknesses

The UK boasts a strong science base and is a global leader in AI innovation, attracting £3.4 billion in private AI investment in 2025. The UK also ranks second for share of government spending on health R&D and joint third for charitable R&D funding. In 2022, pharmaceutical R&D performed by the business enterprise sector in the UK was £9.0 billion, which was equivalent to 0.36% of the UK’s GDP.

However, the UK has been slipping in the rankings for access and uptake of medicines. ABPI data shows that more than 60 medicines/indications did not launch in the UK or were delayed between 2019/20 and 2022/23. High clawback rates on pharmaceutical companies’ revenues, at 23.5% on newer medicines in 2023, dampen investor confidence.

Government Initiatives and Funding

The UK government has launched several initiatives to boost life science innovation. The Life Sciences Innovative Manufacturing Fund (LSIMF) will provide up to £520 million in capital grants for investment in the manufacture of human medicines and medical technology. In March 2023, the UK boosted life science innovation with £277 million funding to four life sciences companies to help fund and advance manufacturing projects in medical diagnostics and human medicines.

The government has also announced new ten-year budgets for R&D funding to give world-class research organizations certainty that their work will be supported during this period. In November 2025, the government awarded more than £54 million across 8 innovative R&D projects through the Sustainable Medicines Manufacturing Innovation Programme.

The US-UK Drug Pricing Deal

In December 2025, the UK agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal that will cost an estimated additional £3bn a year. The transatlantic agreement will also see the health service in England double the percentage of GDP it allocates to buying such products, from 0.3% to 0.6% over the next decade. While ministers said the deal would help boost the pharmaceutical industry in the UK, critics warned that the NHS receives too little funding to absorb the costs involved and that budgets for care, services and treatment must not be raided.

The Role of NICE

The National Institute for Health and Care Excellence (NICE) plays a crucial role in evaluating new treatments and recommending only those that offer value for money for the taxpayer. NICE uses a cost-effectiveness threshold of £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) to appraise new drugs. However, some argue that this threshold is too low and should be increased to reflect the rising costs of drug development.

Striking a Balance

The NHS faces a delicate balancing act. While increased medicine budgets can potentially drive pharmaceutical innovation, it is crucial to ensure that the spending is efficient and delivers real value for patients. Transparency in NHS medicine spending data, including the impact of industry payments, is essential. Reforming pharmaceutical pricing policy and incentivizing the development of truly innovative medicines are also vital steps.

The NHS must also address the factors that attract investment to life sciences, such as taxation, grants, and a skilled workforce. By creating a commercial environment that rewards pharmaceutical innovation fairly and brings its benefits rapidly to UK patients, the NHS can ensure that increased medicine budgets truly drive innovation and improve patient outcomes.

The Future of NHS Spending and Pharma Innovation

The future of NHS spending and pharma innovation hinges on several factors:

Negotiating fair drug prices: The NHS needs to negotiate effectively with pharmaceutical companies to ensure that it is not paying excessive prices for new medicines.
Incentivizing innovation: The government needs to create an environment that encourages pharmaceutical companies to invest in R&D and develop truly innovative medicines.
Improving access to new medicines: The NHS needs to ensure that patients have timely access to new medicines that have been approved by NICE.
Promoting transparency: The NHS needs to be transparent about how it spends its medicines budget and how it makes decisions about which medicines to fund.

By addressing these challenges, the NHS can ensure that increased medicine budgets drive pharmaceutical innovation and improve patient outcomes. The alternative is a system where costs continue to escalate without a corresponding improvement in the health of the population.